“The Expertise of VascularStrategies”
Steven J. Adelman, PhD, FAHA
President and CEO
Steven Adelman co-founded VascularStrategies in 2007. He has served as President and CEO since the company’s inception. As VascularStrategies President and CEO, Dr. Adelman provides leadership and strategic direction for the Company. He is responsible for evaluating and setting the Company’s scientific priorities, coordinating administrative structures and developing business relationships within the scientific and client communities, including identification, implementation and management of research alliances, development collaborations, as well as in-and out-licensing of technologies.
Dr. Adelman received his Ph.D. in biochemistry from the Medical College of Pennsylvania. He has extensive research experience in basic and clinical research of atherosclerotic diseases. With over 20 year of pharmaceutical discovery experience, Dr. Adelman was formerly the Senior Director of Cardiovascular/Metabolic Diseases Research at Wyeth. He was responsible for advancing 10 compounds to clinical trials in cardiovascular, immune disorders and women’s health. Dr. Adelman also played a key role in the collaboration with Cordis/Johnson and Johnson that brought the first drug-eluting stent (Cypher) to market, changing the paradigm for Interventional Cardiology.
A fellow of the American Heart Association (FAHA), Dr. Adelman has more than 15 patents and over 30 peer-reviewed publications.
Heidi L. Collins, Ph.D.
Director of Research
Heidi Collins joined VascularStrategies in 2007 and serves as its Director of Research. Prior to being appointed Director of Research in 2013, Dr. Collins served as the Company’s Laboratory Director. In her current position, Dr. Collins manages all aspects of research services including laboratory operations, client and information services, and quality. She is responsible for providing scientific leadership and technical support to the Company’s laboratory operations and R&D programs. Dr. Collins earned a Ph.D. in Cellular and Molecular Mechanisms of Disease from the Pathology Department of the University of Rochester. She has a broad-based background in a variety of areas but especially in cell-based and in vivo lipoprotein metabolism. Dr. Collins has served as a reviewer for international peer-reviewed journals, presented at scientific meetings, and has over 20 peer-reviewed publications.
In addition to Dr. Adelman-
Daniel J. Rader, M.D., FAHA
Daniel Rader, a founding board member of VascularStrategies, is the Seymour Gray Professor of Molecular Medicine at the University of Pennsylvania Perelman School of Medicine, as well as the Penn CVI Scientific Director for Translational / Clinical Research. Dr. Rader earned his M.D. from the Medical College of Pennsylvania in 1984. He is a recognized expert in cardiovascular medicine, with over 30 years of experience in preclinical lipoprotein metabolism, clinical trials of HDL, Reverse Cholesterol Transport and Atherosclerosis. Dr. Rader has a highly productive academic research program in both basic research and clinical research with a long history of funding from the NIH and American Heart Association. Dr. Rader is a fellow of the American Heart Association with over 250 peer-reviewed publications.
George H. Rothblat, PhD, FAHA
George Rothblat is a Founder of Vascular Strategies LLC and serves as its Board Member. Dr. Rothblat is the Inventor of key IP in RCT technology. He is a pioneer in cellular cholesterol metabolism and world expert on mechanisms of cholesterol transport and cellular cholesterol efflux. Dr. Rothblatt has over 35 years of ground-breaking research with more than 160 peer reviewed manuscripts on mechanisms of atherosclerosis, its mediators, and reversal. His years of work measuring the transfer of cholesterol from cultured macrophages to both animal and human plasma laid the foundation for larger scale clinical studies assessing HDL ‘quality versus quantity’.